Yes, there are ongoing efforts to target Ras mutations therapeutically. Small-molecule inhibitors, such as those targeting the downstream signaling pathways (e.g., MEK inhibitors), have shown promise in preclinical and clinical studies. Additionally, gene therapy approaches and CRISPR-Cas9 mediated gene editing are being explored to specifically target and correct Ras mutations.
